Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
Methods in molecular biology, January 2011
Elisabetta Soragni, Chunping Xu, Andrew Cooper, Heather L. Plasterer, James R. Rusche, Joel M. Gottesfeld, Soragni, Elisabetta, Xu, Chunping, Cooper, Andrew, Plasterer, Heather L., Rusche, James R., Gottesfeld, Joel M.
Various neurodegenerative diseases are associated with aberrant gene expression. We recently identified a novel class of pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD). Here, we describe the various techniques used in our laboratories to dissect mechanisms of gene silencing in FRDA and HD, and to test our HDAC inhibitors for their ability to reverse changes in gene expression in cellular models.
|Readers by professional status||Count||As %|
|Student > Ph. D. Student||12||34%|
|Student > Bachelor||3||9%|
|Student > Postgraduate||3||9%|
|Professor > Associate Professor||3||9%|
|Student > Master||3||9%|
|Readers by discipline||Count||As %|
|Agricultural and Biological Sciences||9||26%|
|Biochemistry, Genetics and Molecular Biology||6||17%|
|Nursing and Health Professions||2||6%|